|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
179 a.a.
|
 |
|
|
|
|
|
|
|
187 a.a.
|
 |
|
|
|
|
|
|
|
14 a.a.
|
 |
|
|
|
|
|
|
|
13 a.a.
|
 |
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Complex (mhc protein/antigen)
|
 |
|
Title:
|
 |
Hla-dr1 (dra, drb1 0101) human class ii histocompatibility protein (extracellular domain) complexed with endogenous peptide
|
|
Structure:
|
 |
Hla-dr1 class ii histocompatibility protein. Chain: a, d, g, j. Fragment: secreted extracellular domains. Synonym: dra, drb1 01010. Engineered: yes. Hla-dr1 class ii histocompatibility protein. Chain: b, e, h, k. Fragment: secreted extracellular domains. Synonym: dra, drb1 01010.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Organ: plasma. Tissue: lymphoid. Cellular_location: plasma membrane. Gene: dra 0101, Drb1 0101. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108.
|
|
Biol. unit:
|
 |
Hetero-Dimer (from PDB file)
|
|
Resolution:
|
 |
|
2.45Å
|
R-factor:
|
0.216
|
R-free:
|
0.279
|
|
|
Authors:
|
 |
V.L.Murthy,L.J.Stern
|
Key ref:
|
 |
V.L.Murthy
and
L.J.Stern
(1997).
The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding.
Structure,
5,
1385-1396.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
28-Jul-97
|
Release date:
|
28-Jan-98
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
|
|
|
P01903
(DRA_HUMAN) -
HLA class II histocompatibility antigen, DR alpha chain
|
|
|
|
Seq: Struc:
|
 |
 |
 |
254 a.a.
179 a.a.
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P04229
(2B11_HUMAN) -
HLA class II histocompatibility antigen, DRB1-1 beta chain
|
|
|
|
Seq: Struc:
|
 |
 |
 |
266 a.a.
187 a.a.
|
|
|
|
|
|
|
 |
 |
|
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
membrane
|
2 terms
|
 |
|
Biological process
|
immune response
|
2 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Structure
5:1385-1396
(1997)
|
|
PubMed id:
|
|
|
|
|
| |
|
The class II MHC protein HLA-DR1 in complex with an endogenous peptide: implications for the structural basis of the specificity of peptide binding.
|
|
V.L.Murthy,
L.J.Stern.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
BACKGROUND: Class II major histocompatibility complex (MHC) proteins are cell
surface glycoproteins that bind peptides and present them to T cells as part of
the mechanism for detecting and responding to foreign material in the body. The
peptide-binding activity exhibits allele-specific preferences for particular
sidechains at some positions, although the structural basis of these preferences
is not understood in detail. We have determined the 2.45 A crystal structure of
the human class II MHC protein HLA-DR1 in complex with the tight binding
endogenous peptide A2 (103-117) in order to discover peptide-MHC interactions
that are important in determining the binding motif and to investigate
conformational constraints on the bound peptide. RESULTS: The bound peptide
adopts a polyproline II-like conformation and places several sidechains within
pockets in the binding site. Bound water molecules mediate MHC-peptide contacts
at several sites. A tryptophan residue from the beta 2 'lower' domain of HLA-DR1
was found to project into a pocket underneath the peptide-binding domain and may
be important in modulating interdomain interactions in MHC proteins.
CONCLUSIONS: The peptide-binding motif of HLA-DR1 includes an aromatic residue
at position +1, an arginine residue at position +2, and a small residue at
position +6 (where the numbering refers to the normal MHC class II convention);
these preferences can be understood in light of interactions observed in the
peptide-MHC complex. Comparison of the structure with that of another
MHC-peptide complex shows that completely different peptide sequences bind in
essentially the same conformation and are accommodated with only minimal
rearrangement of HLA-DR1 residues. Small conformational differences that are
observed appear to be important in interactions with other proteins.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
Figure 2.
Figure 2. Structure of the HLA-DR1-A2 peptide binding site.
(a) Top view of the peptide-binding site, with HLA-DR1 residues
in contact with the peptide indicated with sidechain or
mainchain atoms as appropriate. Atoms are colored by atom type,
with oxygen in red, nitrogen in blue and carbon atoms in green
for the peptide and yellow for HLA-DR1. The peptide residues are
numbered, with Trp(+1) in the principal binding pocket; hydrogen
bonds are shown in magenta. (b) Schematic diagram of peptide
hydrogen-bonding interactions. The peptide sidechains are shown
as R[n] except for arginine at position 2 which contacts the
HLA-DR1 mainchain carbonyl b77 at a kink in the b-chain helical
region. The sidechain of His(+8) is also positioned to form a
hydrogen bond with HLA-DR1 (not shown). The peptide mainchain is
shaded in green. The interactions are color-coded:
HLA-DR1-peptide hydrogen bonds, yellow; hydrogen bonds to buried
water molecules, pink; hydrogen bonds to exposed water
molecules, blue; Arg(+2) guanidinium-HLA-DR1 b77 carbonyl
hydrogen bond, red. (c) Top view of the peptide-binding site,
with the molecular surface indicated by blue dots. A Ca trace
for HLA-DR1 is shown together with a stick model for the A2
peptide and buried water molecules; bonds are colored by atom
type and water molecules are shown as spheres. Not all water
molecules are observed in each molecule in the asymmetric unit.
|
 |
|
|
|
| |
The above figure is
reprinted
by permission from Cell Press:
Structure
(1997,
5,
1385-1396)
copyright 1997.
|
|
| |
Figure was
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
J.Huan,
R.Meza-Romero,
J.L.Mooney,
A.A.Vandenbark,
H.Offner,
and
G.G.Burrows
(2011).
Single-chain recombinant HLA-DQ2.5/peptide molecules block α2-gliadin-specific pathogenic CD4+ T-cell proliferation and attenuate production of inflammatory cytokines: a potential therapy for celiac disease.
|
| |
Mucosal Immunol, 4,
112-120.
|
 |
|
|
|
|
 |
Zaheer-ul-Haq,
and
W.Khan
(2011).
Molecular and structural determinants of adamantyl susceptibility to HLA-DRs allelic variants: an in silico approach to understand the mechanism of MLEs.
|
| |
J Comput Aided Mol Des, 25,
81.
|
 |
|
|
|
|
 |
S.Sadegh-Nasseri,
S.Natarajan,
C.L.Chou,
I.Z.Hartman,
K.Narayan,
and
A.Kim
(2010).
Conformational heterogeneity of MHC class II induced upon binding to different peptides is a key regulator in antigen presentation and epitope selection.
|
| |
Immunol Res, 47,
56-64.
|
 |
|
|
|
|
 |
R.Yaneva,
S.Springer,
and
M.Zacharias
(2009).
Flexibility of the MHC class II peptide binding cleft in the bound, partially filled, and empty states: A molecular dynamics simulation study.
|
| |
Biopolymers, 91,
14-27.
|
 |
|
|
|
|
 |
G.P.Bondinas,
A.K.Moustakas,
and
G.K.Papadopoulos
(2007).
The spectrum of HLA-DQ and HLA-DR alleles, 2006: a listing correlating sequence and structure with function.
|
| |
Immunogenetics, 59,
539-553.
|
 |
|
|
|
|
 |
H.Albrecht,
M.Cosman,
M.Ngu-Schwemlein,
M.Corzett,
K.W.Curran,
C.Dolan,
X.Fang,
S.J.DeNardo,
G.L.DeNardo,
and
R.Balhorn
(2007).
Recombinant expression of the beta-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules.
|
| |
Cancer Biother Radiopharm, 22,
531-542.
|
 |
|
|
|
|
 |
J.M.Kneller,
T.Ehlen,
J.P.Matisic,
D.Miller,
D.Van Niekerk,
W.L.Lam,
M.Marra,
R.Richards-Kortum,
M.Follen,
C.Macaulay,
and
S.J.Jones
(2007).
Using LongSAGE to Detect Biomarkers of Cervical Cancer Potentially Amenable to Optical Contrast Agent Labelling.
|
| |
Biomark Insights, 2,
447-461.
|
 |
|
|
|
|
 |
K.Narayan,
C.L.Chou,
A.Kim,
I.Z.Hartman,
S.Dalai,
S.Khoruzhenko,
and
S.Sadegh-Nasseri
(2007).
HLA-DM targets the hydrogen bond between the histidine at position beta81 and peptide to dissociate HLA-DR-peptide complexes.
|
| |
Nat Immunol, 8,
92.
|
 |
|
|
|
|
 |
A.Mangalam,
M.Rodriguez,
and
C.David
(2006).
Role of MHC class II expressing CD4+ T cells in proteolipid protein(91-110)-induced EAE in HLA-DR3 transgenic mice.
|
| |
Eur J Immunol, 36,
3356-3370.
|
 |
|
|
|
|
 |
J.C.Tong,
J.Bramson,
D.Kanduc,
S.Chow,
A.A.Sinha,
and
S.Ranganathan
(2006).
Modeling the bound conformation of Pemphigus vulgaris-associated peptides to MHC Class II DR and DQ alleles.
|
| |
Immunome Res, 2,
1.
|
 |
|
|
|
|
 |
M.Srinivasan,
D.Lu,
R.Eri,
D.D.Brand,
A.Haque,
and
J.S.Blum
(2005).
CD80 binding polyproline helical peptide inhibits T cell activation.
|
| |
J Biol Chem, 280,
10149-10155.
|
 |
|
|
|
|
 |
T.H.Hansen,
L.Lybarger,
L.Yu,
V.Mitaksov,
and
D.H.Fremont
(2005).
Recognition of open conformers of classical MHC by chaperones and monoclonal antibodies.
|
| |
Immunol Rev, 207,
100-111.
|
 |
|
|
|
|
 |
A.G.Tzakos,
P.Fuchs,
N.A.van Nuland,
A.Troganis,
T.Tselios,
S.Deraos,
J.Matsoukas,
I.P.Gerothanassis,
and
A.M.Bonvin
(2004).
NMR and molecular dynamics studies of an autoimmune myelin basic protein peptide and its antagonist: structural implications for the MHC II (I-Au)-peptide complex from docking calculations.
|
| |
Eur J Biochem, 271,
3399-3413.
|
 |
|
|
|
|
 |
G.J.Carven,
S.Chitta,
I.Hilgert,
M.M.Rushe,
R.F.Baggio,
M.Palmer,
J.E.Arenas,
J.L.Strominger,
V.Horejsi,
L.Santambrogio,
and
L.J.Stern
(2004).
Monoclonal antibodies specific for the empty conformation of HLA-DR1 reveal aspects of the conformational change associated with peptide binding.
|
| |
J Biol Chem, 279,
16561-16570.
|
 |
|
|
|
|
 |
K.Petersson,
G.Forsberg,
and
B.Walse
(2004).
Interplay between superantigens and immunoreceptors.
|
| |
Scand J Immunol, 59,
345-355.
|
 |
|
|
|
|
 |
H.Nojima,
M.Takeda-Shitaka,
Y.Kurihara,
K.Kamiya,
and
H.Umeyama
(2003).
Dynamic flexibility of a peptide-binding groove of human HLA-DR1 class II MHC molecules: normal mode analysis of the antigen peptide-class II MHC complex.
|
| |
Chem Pharm Bull (Tokyo), 51,
923-928.
|
 |
|
|
|
|
 |
M.N.Davies,
C.E.Sansom,
C.Beazley,
and
D.S.Moss
(2003).
A novel predictive technique for the MHC class II peptide-binding interaction.
|
| |
Mol Med, 9,
220-225.
|
 |
|
|
|
|
 |
S.L.Lam,
and
V.L.Hsu
(2003).
NMR identification of left-handed polyproline type II helices.
|
| |
Biopolymers, 69,
270-281.
|
 |
|
|
|
|
 |
Z.Zavala-Ruiz,
E.J.Sundberg,
J.D.Stone,
D.B.DeOliveira,
I.C.Chan,
J.Svendsen,
R.A.Mariuzza,
and
L.J.Stern
(2003).
Exploration of the P6/P7 region of the peptide-binding site of the human class II major histocompatability complex protein HLA-DR1.
|
| |
J Biol Chem, 278,
44904-44912.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
B.J.McFarland,
and
C.Beeson
(2002).
Binding interactions between peptides and proteins of the class II major histocompatibility complex.
|
| |
Med Res Rev, 22,
168-203.
|
 |
|
|
|
|
 |
P.E.Adrian,
G.Rajaseger,
V.S.Mathura,
M.K.Sakharkar,
and
P.Kangueane
(2002).
Types of inter-atomic interactions at the MHC-peptide interface: identifying commonality from accumulated data.
|
| |
BMC Struct Biol, 2,
2.
|
 |
|
|
|
|
 |
T.Areschoug,
S.Linse,
M.Stålhammar-Carlemalm,
L.O.Hedén,
and
G.Lindahl
(2002).
A proline-rich region with a highly periodic sequence in Streptococcal beta protein adopts the polyproline II structure and is exposed on the bacterial surface.
|
| |
J Bacteriol, 184,
6376-6383.
|
 |
|
|
|
|
 |
X.Liu,
S.Dai,
F.Crawford,
R.Fruge,
P.Marrack,
and
J.Kappler
(2002).
Alternate interactions define the binding of peptides to the MHC molecule IA(b).
|
| |
Proc Natl Acad Sci U S A, 99,
8820-8825.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Petersson,
M.Håkansson,
H.Nilsson,
G.Forsberg,
L.A.Svensson,
A.Liljas,
and
B.Walse
(2001).
Crystal structure of a superantigen bound to MHC class II displays zinc and peptide dependence.
|
| |
EMBO J, 20,
3306-3312.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
O.Schueler-Furman,
Y.Altuvia,
and
H.Margalit
(2001).
Examination of possible structural constraints of MHC-binding peptides by assessment of their native structure within their source proteins.
|
| |
Proteins, 45,
47-54.
|
 |
|
|
|
|
 |
A.K.Sato,
J.A.Zarutskie,
M.M.Rushe,
A.Lomakin,
S.K.Natarajan,
S.Sadegh-Nasseri,
G.B.Benedek,
and
L.J.Stern
(2000).
Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1.
|
| |
J Biol Chem, 275,
2165-2173.
|
 |
|
|
|
|
 |
A.Simon,
Z.Dosztányi,
E.Rajnavölgyi,
and
I.Simon
(2000).
Function-related regulation of the stability of MHC proteins.
|
| |
Biophys J, 79,
2305-2313.
|
 |
|
|
|
|
 |
J.R.Cochran,
and
L.J.Stern
(2000).
A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions.
|
| |
Chem Biol, 7,
683-696.
|
 |
|
|
|
|
 |
P.M.Kasson,
J.D.Rabinowitz,
L.Schmitt,
M.M.Davis,
and
H.M.McConnell
(2000).
Kinetics of peptide binding to the class II MHC protein I-Ek.
|
| |
Biochemistry, 39,
1048-1058.
|
 |
|
|
|
|
 |
R.R.Latek,
S.J.Petzold,
and
E.R.Unanue
(2000).
Hindering auxiliary anchors are potent modulators of peptide binding and selection by I-Ak class II molecules.
|
| |
Proc Natl Acad Sci U S A, 97,
11460-11465.
|
 |
|
|
|
|
 |
R.V.Joshi,
J.A.Zarutskie,
and
L.J.Stern
(2000).
A three-step kinetic mechanism for peptide binding to MHC class II proteins.
|
| |
Biochemistry, 39,
3751-3762.
|
 |
|
|
|
|
 |
B.J.McFarland,
A.J.Sant,
T.P.Lybrand,
and
C.Beeson
(1999).
Ovalbumin(323-339) peptide binds to the major histocompatibility complex class II I-A(d) protein using two functionally distinct registers.
|
| |
Biochemistry, 38,
16663-16670.
|
 |
|
|
|
|
 |
B.J.Stapley,
and
T.P.Creamer
(1999).
A survey of left-handed polyproline II helices.
|
| |
Protein Sci, 8,
587-595.
|
 |
|
|
|
|
 |
E.L.Reinherz,
K.Tan,
L.Tang,
P.Kern,
J.Liu,
Y.Xiong,
R.E.Hussey,
A.Smolyar,
B.Hare,
R.Zhang,
A.Joachimiak,
H.C.Chang,
G.Wagner,
and
J.Wang
(1999).
The crystal structure of a T cell receptor in complex with peptide and MHC class II.
|
| |
Science, 286,
1913-1921.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.A.Zarutskie,
A.K.Sato,
M.M.Rushe,
I.C.Chan,
A.Lomakin,
G.B.Benedek,
and
L.J.Stern
(1999).
A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding.
|
| |
Biochemistry, 38,
5878-5887.
|
 |
|
|
|
|
 |
K.Maenaka,
and
E.Y.Jones
(1999).
MHC superfamily structure and the immune system.
|
| |
Curr Opin Struct Biol, 9,
745-753.
|
 |
|
|
|
|
 |
P.S.Andersen,
P.M.Lavoie,
R.P.Sékaly,
H.Churchill,
D.M.Kranz,
P.M.Schlievert,
K.Karjalainen,
and
R.A.Mariuzza
(1999).
Role of the T cell receptor alpha chain in stabilizing TCR-superantigen-MHC class II complexes.
|
| |
Immunity, 10,
473-483.
|
 |
|
|
|
|
 |
R.Wubbolts,
and
J.Neefjes
(1999).
Intracellular transport and peptide loading of MHC class II molecules: regulation by chaperones and motors.
|
| |
Immunol Rev, 172,
189-208.
|
 |
|
|
|
|
 |
C.A.Scott,
P.A.Peterson,
L.Teyton,
and
I.A.Wilson
(1998).
Crystal structures of two I-Ad-peptide complexes reveal that high affinity can be achieved without large anchor residues.
|
| |
Immunity, 8,
319-329.
|
 |
|
PDB codes:
|
 |
|
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
| |